AGMB (AgomAb Therapeutics NV) Debt-to-Equity: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $14.30
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Debt-to-Equity?

AgomAb Therapeutics NV AGMB +1.96% 14 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 104602.41% on this metric.

AgomAb Therapeutics NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.26 Mil. AgomAb Therapeutics NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.05 Mil. AgomAb Therapeutics NV's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $305.73 Mil. AgomAb Therapeutics NV's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AgomAb Therapeutics NV's Debt-to-Equity or its related term are showing as below:

During the past 5 years, the highest Debt-to-Equity Ratio of AgomAb Therapeutics NV was 0.02. The lowest was 0.00. And the median was 0.01.

AGMB's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

AgomAb Therapeutics NV  (NAS:AGMB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AgomAb Therapeutics NV Debt-to-Equity Related Terms

AgomAb Therapeutics NV Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Debt-to-Equity Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
0.02 0.00 0.01 0.01 0.01

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25 Jun26
Debt-to-Equity Get a 7-Day Free Trial 0.01 0.01 0.01 0.01 0.00

AGMB vs CRMD, RGNX, MDXG: Debt-to-Equity Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AgomAb Therapeutics NV Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's Debt-to-Equity falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AgomAb Therapeutics NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.292 + 1.177) / 153.281
=0.01

AgomAb Therapeutics NV's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.264 + 1.048) / 305.733
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
AgomAb Therapeutics NV (AGMB) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 956 companies in the Biotechnology industry.
Is AgomAb Therapeutics NV's Debt-to-Equity too high?
AgomAb Therapeutics NV's current Debt-to-Equity is 0.00. Based on the distribution chart, AgomAb Therapeutics NV ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Debt-to-Equity compare to CRMD and RGNX?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 956 companies for Debt-to-Equity. This places AgomAb Therapeutics NV in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.30
Price